The Role of Eph Receptors and Ephrins in Corneal Physiology and Diseases.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
27 Apr 2021
Historique:
received: 02 04 2021
revised: 21 04 2021
accepted: 26 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 4 6 2021
Statut: epublish

Résumé

The cornea, while appearing to be simple tissue, is actually an extremely complex structure. In order for it to retain its biomechanical and optical properties, perfect organization of its cells is essential. Proper regeneration is especially important after injuries and in the course of various diseases. Eph receptors and ephrin are mainly responsible for the proper organization of tissues as well as cell migration and communication. In this review, we present the current state of knowledge on the role of Eph and ephrins in corneal physiology and diseases, in particular, we focused on the functions of the epithelium and endothelium. Since the role of Eph and ephrins in the angiogenesis process has been well established, we also analyzed their influence on conditions with corneal neovascularization.

Identifiants

pubmed: 33925443
pii: ijms22094567
doi: 10.3390/ijms22094567
pmc: PMC8123804
pii:
doi:

Substances chimiques

Ephrins 0
Receptors, Eph Family EC 2.7.10.1

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Int J Ophthalmol. 2015 Feb 18;8(1):182-93
pubmed: 25709930
Nat Biomed Eng. 2020 Nov;4(11):1053-1062
pubmed: 32895514
Acta Ophthalmol. 2011 Feb;89(1):82-90
pubmed: 19764912
Mol Vis. 2006 Jan 23;12:55-64
pubmed: 16446702
Invest Ophthalmol Vis Sci. 2011 May 17;52(6):3301-8
pubmed: 21330660
Prog Retin Eye Res. 2007 Jul;26(4):359-78
pubmed: 17446115
Cont Lens Anterior Eye. 2019 Oct;42(5):575-580
pubmed: 31064697
Arch Soc Esp Oftalmol. 2006 Jun;81(6):309-12
pubmed: 16804772
Exp Eye Res. 2013 Feb;107:110-20
pubmed: 23247085
Adv Cancer Res. 2020;147:303-317
pubmed: 32593404
Curr Eye Res. 1991 Feb;10(2):145-56
pubmed: 1645240
Regen Med. 2019 May;14(4):257-261
pubmed: 31070511
Neuroscience. 2005;135(1):97-109
pubmed: 16054765
J Cell Sci. 2002 Aug 1;115(Pt 15):3073-81
pubmed: 12118063
Br J Ophthalmol. 2010 Dec;94(12):1668-73
pubmed: 20934994
Circulation. 2005 May 3;111(17):2210-8
pubmed: 15851594
Int J Clin Exp Med. 2014 Nov 15;7(11):4008-15
pubmed: 25550909
PLoS One. 2011 Mar 30;6(3):e18128
pubmed: 21479221
Pharmacol Res Perspect. 2019 Nov 20;7(6):e00545
pubmed: 31763044
Am J Pathol. 2006 Jan;168(1):331-9
pubmed: 16400034
Sci Rep. 2018 Jan 24;8(1):1539
pubmed: 29367676
Prog Retin Eye Res. 2010 May;29(3):208-48
pubmed: 20100589
Br J Clin Pharmacol. 2018 May;84(5):865-875
pubmed: 29315699
Drug Discov Today. 2014 May;19(5):661-9
pubmed: 24291785
Microvasc Res. 2009 May;77(3):382-6
pubmed: 19232363
Nutr Diabetes. 2017 Mar 20;7(3):e251
pubmed: 28319106
Can J Ophthalmol. 2009 Apr;44(2):185-8
pubmed: 19491953
Cell Adh Migr. 2014;8(4):327-38
pubmed: 25482622
Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):393-406
pubmed: 29351356
Exp Eye Res. 2004 Mar;78(3):433-46
pubmed: 15106923
Cytokine Growth Factor Rev. 2004 Dec;15(6):419-33
pubmed: 15561600
J Cataract Refract Surg. 2011 Mar;37(3):588-98
pubmed: 21333881
Pharmaceuticals (Basel). 2020 May 08;13(5):
pubmed: 32397088
Cornea. 2011 Aug;30(8):927-38
pubmed: 21389854
J Cell Mol Med. 2012 Dec;16(12):2894-909
pubmed: 22862837
Annu Rev Pharmacol Toxicol. 2015;55:465-87
pubmed: 25292427
F1000Res. 2016 Mar 30;5:
pubmed: 27092247
Invest Ophthalmol Vis Sci. 2003 Jul;44(7):2941-8
pubmed: 12824235
Science. 1995 Apr 28;268(5210):567-9
pubmed: 7536959
Invest Ophthalmol Vis Sci. 2012 Feb 23;53(2):936-45
pubmed: 22247486
Trends Cardiovasc Med. 2007 Jul;17(5):145-51
pubmed: 17574121
Oncogene. 2000 Dec 7;19(52):6043-52
pubmed: 11146556
Rom J Morphol Embryol. 2011;52(3):837-44
pubmed: 21892527
Recent Results Cancer Res. 2018;212:29-68
pubmed: 30069624
Exp Eye Res. 2020 Sep;198:108094
pubmed: 32697979
Prog Retin Eye Res. 2015 Nov;49:1-16
pubmed: 26145225
J Ophthalmic Vis Res. 2017 Apr-Jun;12(2):193-204
pubmed: 28540012
Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):2008-14
pubmed: 14500293
Cell Mol Life Sci. 2003 Jun;60(6):1135-57
pubmed: 12861381
Trans Am Ophthalmol Soc. 2006;104:264-302
pubmed: 17471348
Angiogenesis. 2004;7(1):17-28
pubmed: 15302992
Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2175-82
pubmed: 15914639
Exp Eye Res. 2018 May;170:92-100
pubmed: 29476773
Cancer Res. 2004 Feb 1;64(3):910-9
pubmed: 14871820
Cell Mol Life Sci. 2012 Jun;69(11):1813-42
pubmed: 22204021
Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4772-9
pubmed: 16303978
Surv Ophthalmol. 1998 Nov-Dec;43(3):245-69
pubmed: 9862312
Cornea. 2007 Jun;26(5):569-78
pubmed: 17525654
Curr Eye Res. 2013 Dec;38(12):1191-7
pubmed: 24047084
Mol Cancer Res. 2002 Nov;1(1):2-11
pubmed: 12496364
Adv Exp Med Biol. 2018;1085:227-232
pubmed: 30578521
Cell. 2008 Apr 4;133(1):38-52
pubmed: 18394988
Ocul Surf. 2019 Oct;17(4):644-654
pubmed: 31238114
J Cell Sci. 2008 Nov 15;121(Pt 22):3842-50
pubmed: 18957513
Rom J Ophthalmol. 2019 Jan-Mar;63(1):15-22
pubmed: 31198893
Invest Ophthalmol Vis Sci. 1996 Jul;37(8):1625-32
pubmed: 8675406

Auteurs

Radoslaw Kaczmarek (R)

Department of Ophthalmology, Wroclaw Medical University, 50-556 Wroclaw, Poland.

Katarzyna Zimmer (K)

Department of Ophthalmology, Wroclaw Medical University, 50-556 Wroclaw, Poland.

Pawel Gajdzis (P)

Department of Pathomorphology and Oncological Cytology, Wroclaw Medical University, 50-556 Wroclaw, Poland.

Malgorzata Gajdzis (M)

Department of Ophthalmology, Wroclaw Medical University, 50-556 Wroclaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH